Clinical trials: multiple sclerosis
Drug-resistant Focal Epilepsies in Pediatric Population
Genetic and Electrophysiologic Study in Focal Drug-resistant Epilepsies
Brain somatic mutations are increasingly recognized as a major cause of focal epilepsies. These include mTOR pathway mutations underlying cortical malformations such as focal cortical dysplasia and hemimegalencephaly, and SLC35A2…
- Trial name
- GENEPHY (NCT02890641)
- Testing
- Sampling of blood, frozen resected tissues, and cerebrospinal fluid (CSF)
- Where
- France
- Volunteers
- 450 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Multiple Sclerosis
Evaluation of the Effect of Mental Imagery Training Combined With Modified Constraint-Induced Movement Therapy in Individuals With Multiple Sclerosis
This study aims to investigate the effects of mental imagery training combined with modified constraint-induced movement therapy in individuals with multiple sclerosis.
- Trial name
- NCT07899411
- Testing
- odified Constraint-Induced Movement Therapy + Mental Imagery Training, Modified Constraint-Induced Movement Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 14 people
- Sponsor
- Hacettepe University
Relapsing Multiple Sclerosis
A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
To make laquinimod 0.6 mg available for all subjects who completed the placebo-controlled MS-LAQ-302 study according to the protocol and to evaluate the long-term safety, tolerability and effect on disease course of daily oral…
- Trial name
- NCT01047319
- Testing
- Laquinimod
- Where
- 144 sites in United States, Bulgaria and 16 more
- Volunteers
- 1,047 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Tuberous Sclerosis Complex
Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship
Tuberous Sclerosis is a rare genetic disorder that affects about one in 15,000 individuals. It is part of the phacomatoses: a germline mutation of the gene Tuberous Sclerosis Complex 1 (TSC1) or TSC2 causes a protein dysfunction…
- Trial name
- NCT04112537
- Where
- France
- Volunteers
- 90 people
- Sponsor
- University Hospital, Montpellier
Multiple Sclerosis
An Observational Study to Document the Effectiveness and Compatibility of Rebif 44 or 22 µg in the Therapy of the Chronic Multiple Sclerosis
The aim of this case series was to document the effectiveness and compatibility of Rebif 44 or 22 µg in the therapy of the chronic multiple sclerosis (MS) under practical conditions on a large collection of subjects.
- Trial name
- NCT01142557
- Testing
- Interferon beta-1a (Rebif)
- Where
- Germany
- Volunteers
- 522 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis
Demographics, Clinical and Paraclinical Characteristics of Multiple Sclerosis in Egypt
The primary study aim is to depict the demographics, clinical and para clinical features of patients attending five tertiary referral multiple sclerosis (MS) centers in Egypt.
- Trial name
- NCT02970370
- Testing
- no intervention
- Volunteers
- 2,752 people
- Sponsor
- Cairo University
Tuberous Sclerosis Complex
Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)
Tuberous Sclerosis Complex (TSC) is a multi-system disease, usually presenting with seizures, mental retardation and autism, and exhibiting a high variability in clinical findings both among and within families.
- Trial name
- TSC (NCT01289912)
- Testing
- RAD001
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- Mustafa Sahin
Multiple Sclerosis
Costs, Quality of Life and Functional Outcomes in Veterans Treated for Multiple Sclerosis With Beta-Interferon l-B (Betaseron)
The treatment of multiple sclerosis was evolving in light of specific drug therapies to treat the disease, refinements and acceptance of imaging with MRI to diagnose and monitor the disease process, and progress in understanding…
- Trial name
- NCT00439257
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- US Department of Veterans Affairs
Central Nervous System Disease, Multiple Sclerosis
Comprehensive Multimodal Analysis of Neuroimmunological Diseases of the Central Nervous System
Inflammatory or degenerative diseases of the brain and spinal cord, such as multiple sclerosis, may be related to problems with an individual s immune system.
- Trial name
- NCT00794352
- Where
- United States
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Multiple Sclerosis
A Retrospective Study to Understand the Clinical Management of Subjects With Multiple Sclerosis at a Site in Taiwan Over the Last 10 Years
This is an observational, non comparative, non-randomised, open-label, retrospective, single centre study planned to collect the data of subjects diagnosed with multiple sclerosis (MS) as per Poser or McDonald criteria between…
- Trial name
- NCT01084798
- Where
- Taiwan
- Volunteers
- 123 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Tuberous Sclerosis Complex
Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC
The purpose of this study is to investigate the efficacy and safety of NPC-12Y gel compared with placebo for skin lesions associated with tuberous sclerosis.
- Trial name
- NCT05495425
- Testing
- NPC-12Y gel
- Where
- 5 sites in Japan
- Volunteers
- 43 people
- Sponsor
- Nobelpharma
Clinically Isolated Syndrome, Radiologically Isolated Syndrome
Isoelectric Focusing of Tears in Children With Radiologically Isolated or Clinically Isolated Syndrome
The main gold of this study is to lead a multicentric, prospective study, to evaluate the diagnostic quality of tears in children with clinically isolated syndrome (CIS) and radiologically isolated syndrome (RIS) during a…
- Conditions
- Clinically Isolated Syndrome, Radiologically Isolated Syndrome, Multiple Sclerosis in Children
- Trial name
- OBIT (NCT03979391)
- Testing
- Tear collection and lumbar punction
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Lille Catholic University
Multiple Sclerosis
Re-training to Effort (RE) According to the Severity of Multiple Sclerosis: Preliminary Assessments Based on Fatigue and Quality of Life
Regular physical activity promotes physical and mental well-being in the general population. Patients with multiple sclerosis (MS patients) tend them, to limit their physical activity or because of deficiencies related to the…
- Trial name
- RE-SEP (NCT02848976)
- Testing
- Re-training to effort (RE)
- Where
- France
- Volunteers
- 32 people
- Sponsor
- Nantes University Hospital
Multiple Sclerosis (MS)
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis
- Trial name
- NEOS (NCT04926818)
- Testing
- Fingolimod, Ofatumumab, Siponimod
- Where
- 51 sites in United States, Argentina and 23 more
- Volunteers
- 129 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Rolipram to Treat Multiple Sclerosis
This study will evaluate the safety, tolerability, and effect of the drug Rolipram on multiple sclerosis (MS). It will examine whether Rolipram can dampen the part of the immune response believed to lead to MS and reduce disease…
- Trial name
- NCT00011375
- Testing
- Rolipram
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Trigeminal Neuralgia, Multiple Sclerosis
Symptomatic Trigeminal Neuralgia Attributed to Multiple Sclerosis - a Prospective Study in 60 Patients
Clinical characteristics, neuroanatomical findings and efficacy of medical and surgical treatment of symptomatic trigeminal neuralgia - a systematic prospective study of 60 consecutive patients
- Conditions
- Trigeminal Neuralgia, Multiple Sclerosis, Pain, Neuropathic
- Trial name
- NCT04371575
- Testing
- Carbamazepine
- Volunteers
- 60 people
- Sponsor
- Stine Maarbjerg, MD PhD
Tuberous Sclerosis Complex
Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex
The purpose of the RaRE-TS study is to determine safety, tolerability and efficacy of rapamycin versus placebo in a drug resistant epilepsy associated with tuberous sclerosis complex (TSC).
- Trial name
- RaRE-TS (NCT05534672)
- Testing
- Rapamycin
- Where
- 2 sites in Poland
- Volunteers
- 200 people
- Sponsor
- Katarzyna Kotulska
Multiple Sclerosis, Malignant Tumor
Drugs for the Treatment of Multiple Sclerosis and Risk of Cancer: a Pharmacovigilance Analysis in Vigibase
Even though the therapeutic panel for multiple sclerosis (MS) treatment has improved in the last 20 years, safety data especially for the second-line and innovative treatments are lacking.
- Trial name
- PVSEPK (NCT04237337)
- Testing
- Exposure to MS drugs
- Volunteers
- 200,000 people
- Sponsor
- University Hospital, Caen
Tuberous Sclerosis, Lymphangioleiomyomatosis
Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma
Tuberous Sclerosis Complex (TSC) is a multisystemic autosomal dominant disease that is characterized by the development of benign neoplasms in brain, kidney, lung, skin and heart.
- Conditions
- Tuberous Sclerosis, Lymphangioleiomyomatosis, Angiomyolipoma
- Trial name
- NCT02325505
- Where
- 3 sites in Brazil
- Volunteers
- 200 people
- Sponsor
- InCor Heart Institute
Multiple Sclerosis, Ataxia
"Evaluation of Usability and Safety of the Self-balancing Walking System Atalante in Patients With Multiple Sclerosis"
Multiple sclerosis (MS) is the most prevalent chronic inflammatory disease of the central nervous system (CNS), affecting more than 2 million people worldwide,1 it is a degenerative disease that selectively affects the central…
- Conditions
- Multiple Sclerosis, Ataxia, Paraplegia
- Trial name
- EXO (NCT05563402)
- Testing
- Atalante
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Multiple Sclerosis Center of Catalonia